STOCK TITAN
  1. Home
  2. News
  3. PMVP

PMV Pharmaceuticals, Inc - $PMVP STOCK NEWS

Welcome to our dedicated page for PMV Pharmaceuticals news (Ticker: $PMVP), a resource for investors and traders seeking the latest updates and insights on PMV Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PMV Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PMV Pharmaceuticals's position in the market.

News
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rhea-AI Summary
PMV Pharmaceuticals announces dosing of the first patient in the Phase 2 trial of rezatapopt for advanced solid tumors with TP53 Y220C mutation and KRAS wild-type.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
clinical trial
-
News
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Rhea-AI Summary
PMV Pharmaceuticals reports promising Phase 1 analysis results of rezatapopt in advanced ovarian cancer patients with TP53 Y220C mutation at 2024 SGO Annual Meeting. Seven out of 15 patients achieved a confirmed partial response with a seven-month median duration of response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
clinical trial
-
News
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (PMVP) reports progress on rezatapopt, a precision oncology investigational therapy. Phase 2 trial set to start in Q1 2024. Cash position at $228.6 million. Corporate restructuring to extend cash runway to 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
earnings
News
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (PMVP) CEO to participate in TD Cowen 44th Annual Health Care Conference. The company focuses on developing tumor-agnostic therapies targeting p53.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
conferences
-
News
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (PMVP) announced a 30% reduction in its workforce to prioritize the development of PC14586 and focus on discovery research. The company expects the cost savings from this reduction, combined with its unaudited cash, cash equivalents, and marketable securities of approximately $229 million as of December 31, 2023, to extend its cash runway to the end of 2026. PMVP also plans to initiate the registrational Phase 2 clinical trial for PC14586 in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
clinical trial
-
News
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
Rhea-AI Summary
PMV Pharmaceuticals, a precision oncology company (Nasdaq: PMVP), announced key leadership appointments and promotions. The PC14586 clinical program will be led by Deepika Jalota, Pharm.D. and Marc Fellous, M.D. The registrational Phase 2 clinical trial remains on track to initiate in Q1 2024. Michael Carulli has been promoted to Chief Financial Officer. Robert Ticktin, General Counsel, will expand responsibilities to include management of Operations. Tim Smith, Senior Vice President, Head of Corporate Development, will expand responsibilities to include Investor Relations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (PMVP) reports updated data from Phase 1 PYNNACLE clinical trial of PC14586, demonstrating a 38% overall response rate and median duration of response of seven months across multiple tumor types. Registrational Phase 2 clinical trial expected to initiate in Q1 2024. Financial results for Q3 2023 show $238.1 million in cash, net loss of $53.2 million, and ongoing enrollment in combination arm of PYNNACLE study with PC14586 and KEYTRUDA®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
earnings
-
News
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Rhea-AI Summary
PMV Pharmaceuticals announces positive Phase 1 results for PC14586 in multiple tumor types
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.58%
Tags
clinical trial
-
News
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
Rhea-AI Summary
PMV Pharmaceuticals to present updated Phase 1 data at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.01%
Tags
conferences clinical trial
News
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Summary
PMV Pharmaceuticals to present updated Phase 1 data of PC14586 at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences clinical trial
Stock PMVP logo
PMV Pharmaceuticals, Inc

Nasdaq:PMVP

PMVP Rankings

#4273 Ranked by Market Cap
#5458 Ranked by Stock Gains
N/A Ranked by Dividends

PMVP Stock Data

102.37M
41.01M
2.95%
99.55%
5.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About PMVP

pmv pharmaceuticals, inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. its lead product candidate is pc14586, a small molecule that corrects and restores p53 function. the company also develops product candidates for p53 r273h hotspot mutation and other p53 hotspot mutations. pmv pharmaceuticals, inc. was formerly known as pj pharmaceuticals, inc. and changed to in july 2013. the company was founded in 2013 and is headquartered in cranbury, new jersey.